Sotera Health Company (NASDAQ:SHC) Q2 2024 Earnings Conference Call August 5, 2024 9:00 AM ET Company Participants Jason Peterson - VP & Treasurer Michael Petras - Chairman & CEO Jonathan Lyons - SVP & CFO Conference Call Participants Dave Windley - Jefferies Brett Fishbin - KeyBanc Capital Markets Patrick Donnelly - Citigroup Inc. Casey Woodring - J.P. Morgan Chase Salem Salem - Barclays Jason Bednar - Piper Sandler Michael Polark - Wolfe Research Operator Good morning, and welcome to the Sotera Health Sec ...

Exhibit 99.1 Sotera Health Reports Second-Quarter and First-Half 2024 Results • Q2 2024 net revenues of $277 million increased 8%, compared to Q2 2023 • Q2 2024 net income of $9 million or $0.03 per diluted share, compared to net income of $24 million or $0.08 per diluted share in Q2 2023 • Q2 2024 Adjusted EBITDA of $137 million increased 7%, compared to Q2 2023 • Q2 2024 Adjusted EPS of $0.19 declined $0.01 per diluted share, compared to Adjusted EPS of $0.20 in Q2 2023 • Successfully refinanced debt stru ...

Q2 2024 net revenues of $277 million increased 8%, compared to Q2 2023 Q2 2024 net income of $9 million or $0.03 per diluted share, compared to net income of $24 million or $0.08 per diluted share in Q2 2023 Q2 2024 Adjusted EBITDA(1) of $137 million increased 7%, compared to Q2 2023 Q2 2024 Adjusted EPS(1) of $0.19 declined $0.01 per diluted share, compared to Adjusted EPS of $0.20 in Q2 2023 Successfully refinanced debt structure, extending debt maturities to 2031 Reaffirming 2024 outlook CLEVELAND, Aug. ...

Q2 2024 net revenues of $277 million increased 8%, compared to Q2 2023 Q2 2024 net income of $9 million or $0.03 per diluted share, compared to net income of $24 million or $0.08 per diluted share in Q2 2023 Q2 2024 Adjusted EBITDA(1) of $137 million increased 7%, compared to Q2 2023 Q2 2024 Adjusted EPS(1) of $0.19 declined $0.01 per diluted share, compared to Adjusted EPS of $0.20 in Q2 2023 Successfully refinanced debt structure, extending debt maturities to 2031 Reaffirming 2024 outlook CLEVELAND, Aug. ...

Core Insights - Sotera Health Company has appointed Christopher Simon as a new independent director to its Board of Directors, enhancing its leadership team [1][3] - Mr. Simon brings over 30 years of experience in the healthcare industry, including roles as President and CEO of Haemonetics Corporation and Senior Partner at McKinsey & Company [2][3] - Sotera Health operates through three business units: Sterigenics®, Nordion®, and Nelson Labs®, focusing on sterilization solutions and lab testing services for the healthcare sector [4] Company Overview - Sotera Health is a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry [4] - The company is committed to its mission of "Safeguarding Global Health®" [4] Leadership Experience - Christopher Simon's leadership experience as a public company CEO and his strategic background in the life sciences industry are expected to be significant assets for Sotera Health's growth [3] - Mr. Simon also serves on the board of directors of AdvaMed, a global trade association for medical technology companies [3]

Updates can be found from time to time on recent developments in matters relevant to investors on the Investor Relations section of the Company's website at Investor Relations | Sotera Health. For developments related to Ethylene Oxide, updates can be found at Ethylene Oxide | Sotera Health. Contacts Source: Sotera Health Company To participate in the live call, please dial 1-844-481-2916 if dialing-in from the United States, or 1-412-317- 0709 if dialing-in from other locations. A live webcast of the confe ...

To participate in the live call, please dial 1-844-481-2916 if dialing-in from the United States, or 1-412-317- 0709 if dialing-in from other locations. A live webcast of the conference call can be accessed at this link or via the Investor Relations section of the Company's website at Presentation & Events | Sotera Health, along with the accompanying materials. A replay of the webcast will be available later in the day on August 5th. Jason Peterson Vice President & Treasurer, Sotera Health IR@soterahealth.c ...

CLEVELAND, May 30, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company ("Sotera Health" or the "Company") (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, today announced that its direct subsidiary has successfully closed a new senior secured Term Loan B facility in an aggregate principal amount of $1.51 billion (the "TLB") as well as an issuance of senior secured notes in an aggregate principal amou ...

CLEVELAND, May 30, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company ("Sotera Health" or the "Company") (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, today announced that its direct subsidiary has successfully closed a new senior secured Term Loan B facility in an aggregate principal amount of $1.51 billion (the "TLB") as well as an issuance of senior secured notes in an aggregate principal amou ...

Sotera Health Company (NASDAQ:SHC) Q1 2024 Earnings Conference Call May 2, 2024 9:00 AM ET Company Participants Jason Peterson - VP and Treasurer Michael B. Petras - Chairman and CEO Jonathan M. Lyons - SVP and CFO Conference Call Participants Patrick Donnelly - Citigroup Inc. Sean Dodge - RBC Capital Markets Casey Woodring - J.P. Morgan Chase Unidentified Analyst - Barclays Brett Fishbin - KeyBanc Capital Markets Michael Polark - Wolfe Research Operator Good morning, and welcome to the Sotera Health First ...